Probiotic yogurt improves antioxidant status in type 2 diabetic patients.

Faculty of Health and Nutrition, Tabriz University of Medical Sciences, Tabriz, Iran.
Nutrition (Impact Factor: 2.86). 11/2011; 28(5):539-43. DOI: 10.1016/j.nut.2011.08.013
Source: PubMed

ABSTRACT Oxidative stress plays a major role in the pathogenesis and progression of diabetes. Among various functional foods with an antioxidant effect, probiotic foods have been reported to repress oxidative stress. The objective of this clinical trial was to assess the effects of probiotic and conventional yogurt on blood glucose and antioxidant status in type 2 diabetic patients.
Sixty-four patients with type 2 diabetes mellitus, 30 to 60 y old, were assigned to two groups in this randomized, double-blind, controlled clinical trial. The patients in the intervention group consumed 300 g/d of probiotic yogurt containing Lactobacillus acidophilus La5 and Bifidobacterium lactis Bb12 and those in the control group consumed 300 g/d of conventional yogurt for 6 wk. Fasting blood samples, 24-h dietary recalls, and anthropometric measurements were collected at the baseline and at the end of the trial.
Probiotic yogurt significantly decreased fasting blood glucose (P < 0.01) and hemoglobin A1c (P < 0.05) and increased erythrocyte superoxide dismutase and glutathione peroxidase activities and total antioxidant status (P < 0.05) compared with the control group. In addition, the serum malondialdehyde concentration significantly decreased compared with the baseline value in both groups (P < 0.05). No significant changes from baseline were shown in insulin concentration and erythrocyte catalase activity within either group (P > 0.05).
The consumption of probiotic yogurt improved fasting blood glucose and antioxidant status in type 2 diabetic patients. These results suggest that probiotic yogurt is a promising agent for diabetes management.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Besides their basic nutritional role, dietary proteins contain bioactive peptides which are encrypted in their sequence and may modulate different body functions such as digestive, cardiovascular, immune and nervous systems, and therefore contribute in maintaining consumer health. Currently, milk proteins are considered to be the major source of bioactive peptides. The occurrence of these peptides has already been reported in fermented milk products such as yogurt, sour milk or kefir and some of them have been shown to confer health benefits. This review focuses on different strategies that could be employed to enhance the production of bioactive peptides from the milk proteins that will be consequently used to functionalize the fermented milk products. Three types of strategies are developed. The first exploits the proteolytic system of lactic acid bacteria (LAB) or food grade enzymes or combination of both to release the functional peptides from the milk proteins directly in the fermented milk products. The second concerns the supplementation of the fermented milk products with the bioactive peptides obtained outside of the product through the hydrolysis of the purified proteins by the same enzyme sources. Finally, the last consists in the production of the bioactive peptides, initially identified from the milk-proteins, by microorganisms using recombinant DNA technology.
    Food Research International 09/2014; 63(partA):71-80. · 3.05 Impact Factor
  • Source
    Journal of food and nutrition research 01/2014; 2(8):491-98. · 0.60 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Rats fed high fat diets have alterations of their intestinal microbiota, gut barrier function, circulating lipopolysaccharide (LPS) levels and biomarkers of oxidative stress, inflammation, and glucose/insulin metabolism, resulting in a higher risk of type-2 diabetes. These deleterious effects are prevented by antibiotics or prebiotics. The aim of this study was to determine whether the administration of a synbiotic improves metabolic alterations and low grade inflammation in obese subjects. A randomized, double-blind, controlled clinical trial (, Access Number NCT01235026) was carried out in 40 obese patients. Subjects were distributed in two groups to receive 8g oligofructose + 1 g of lyophilized Bifidobacterium lactis Bb12 (1010 CFU/g) or 9g maltodextrin as placebo, twice a day for six weeks. Body composition, blood lipids, antioxidant capacity of plasma, biomarkers of inflammation (usCRP, IL-6) and LPS exposure (LPS-Binding Protein, LBP, and sCD14), areas under curves of glycemia and insulinemia and fecal microbiota (qPCR) were quantified at baseline and after treatment. 38 subjects (34.8 ± 9.2y; BMI: 36.7 ± 5.3 kg.m-2) completed the study. A positive correlation was observed at baseline between usCRP, IL-6, LBP, sCD14 and the percentage of body fat; correlations also existed between usCRP, IL-6 and LBP values while sCD14 only correlated with IL-6. Compared with placebo, the administration of synbiotic increased the fecal levels of Bifidobacterium spp. but did not affect body composition, lipid profile, antioxidant status and areas under curves of glycemia and insulinemia, nor the plasma concentrations of usCRP, IL-6 and LBP. Plasma concentrations of sCD14 were significantly lower after treatment in the symbiotic group compared with the placebo 3 group (5.98 μg/ml [5.01-6.96] vs. 7.26 [6.34-8.09] μg/ml (Means [CI95%), respectively; p=0.043). The synbiotic increased fecal bifidobacteria in obese subjects without improvement the biochemical, inflammatory and metabolic markers; more studies are required to elucidate the role of the symbiotic on plasma sCD14.
    08/2014; 2(2):491-498.


Available from
Aug 23, 2014